Mustikjad Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA) ("Company" or "Blueberry"), a manufacturer of Latin American hashish and hashish products, has signed a last three way partnership settlement ( "agreement" with the Worldwide Center for Research on Cannabis and Mental Health ("IRCCMH" or "Center") for the improvement of medical training programs for docs and patients in Latin America and the product range.
IRCCMH is a number one cannabis analysis and educational organization with in depth expertise in hashish research and schooling, pharmacology, product design and efficacy of cannabis remedies. The New York Silver Faculty in New York, IRCCMH is made up of well-known scientists, academics and docs and was established to bridge the hole between research and medical follow. IRCCMH also develops training programs for docs and patients and advises on numerous government-sponsored medical hashish programs and has directed state regulators to establish and implement cannabis programs in Pennsylvania, Delaware, New Jersey, Utah, California and different nations. The founders, founders and employees of Jan Roberts, LCSW and Jahan Marcu, Ph.D.
”This co-operation settlement with IRCCMH offers a superb alternative for blueberries to make the most of the in-depth experience of IRCCMH in training Latin American docs and creating drug remedy for sufferers in the Latin American market and beyond. As the regulation of cannabis develops globally, schooling and consciousness are of paramount importance for its introduction and for strengthening the benefits of early transition, ”stated Dr. Patricio Stocker. “IRCCMH is a respected institution in the United States, and their focus on education and research is consistent with our goal of providing efficient and responsible treatment to many patients and clients worldwide. The agreement emphasizes the teaching of doctors and patients and provides educational tools for all parties. This alliance will ensure that we develop products and treatments for the medical community, and the process will be simplified to reach patients in these emerging markets. initiatives. Blueberries, together with IRCCMH, are developing a treatment-centered medical training program to help doctors define cannabis treatment plans for patients (the “program”) in Latin America. The great patient and medical training program is Blueberries' strategy for introducing and implementing hashish remedies. Blueberries are placed as an early leader in the Latin American cannabis market.
”IRCCMH is happy to cooperate with Blueberry Drugs and the alternative to make the most of our experience in cannabis remedy, analysis and schooling in the fast-growing international marketplace,” stated Jan Roberts, founder of IRCCMH, “This association will assist blueberries to grow to be a pacesetter in the remedy of medical hashish in Latin America and to be sure that IRCCMH's analysis, training and unique expertise will increasingly affect the remedy of hashish in this area of the world.
This initiative was originally launched by the firm beforehand introduced a partnership with El Manantial Medical Facilities in Bogota Enlargement, Assets, Sufferers and Expertise required to launch the program and develop business compositions and merchandise in collaboration with IRCCMH. Blueberries proceed their network of sufferers and docs by replicating the El Manantial Medical Center with different docs, institutions and medical organizations
In addition to creating the greatest classroom training program for docs and sufferers in Latin America, entry to a gaggle of IRCCMH specialists with profound medical expertise cannabis, facilitates product improvement and creates applicable formulations and merchandise to velocity up product standardization by commercializing the company's cannabis products by way of the quick growing affected person base of the El Manantial Medical Center
About IRCCMH and Founders of IRCCMH
Situated in New York based mostly on years of expertise in cannabis and mental well being in the United States. The aim of IRCCMH was to remove the hole between research and medical apply. IRCCMH was founded by Jan Roberts and Dr. Jahan Marcu in 2017 to provide high quality research and training to the cannabis drugs group. IRCCMH is a community-based institute in New York that works with universities, researchers, foundations, state establishments, and different organizations to capitalize on the greatest in the business. The Institute is working on constructing training seminars, expanding research with universities, and enhancing session with healthcare professionals and regulatory our bodies to improve affected person care. Via lots of its tasks, Marcu and Roberts have helped to establish a dialogue in the area of cannabis schooling and research that had not been beforehand mentioned.
For additional info: www.irccmh.org/about-irccmh
Jan Roberts, LCSW: Managing Director and Director of Conversion Research
Jan Roberts is IRCCMH and serves as Managing Director and Director of Translation Research. Roberts is a licensed medical social worker who owns and uses one in every of the largest collaborative care practices in the mid-Atlantic – Health and Wellbeing Partners. Roberts is a physician and entrepreneur with an activist spirit and in depth experience of both non-profit and profit-seeking healthcare organizations.
Ms. Roberts teaches at NYU's Silver Faculty of Social Work and is presently working on a funded research of mental health clinics and information and attitudes about cannabis. He’s also a visitor author for the Cannabis and Mental Health concern in the Medical Social Work Journal (CSWJ).
Ms. Roberts' current work focuses on the medical software of hashish in mental health issues and focuses on maladaptive survival strategies relatively than on the material strategy to treating addictions. Consequently, Roberts is especially taken with educating other psychological health practitioners about the newest research findings about the lack of shame and information of cannabis, endocannabinoid and psychological health outcomes
Jahan Marcu, Ph.D. D., founding father of IRCCMH. Dr. Marcu is a former American science manager for protected access (a medical cannabis non-profit) and former affected person's central certification program supervisor, a health and safety monitoring program that evaluates compliance with cannabis rules. 19659002] He’s the founder and former chairman of the CANN division of the Chemical Chemical and Safety Department of the American Chemical Society (DCHAS). He’s additionally on the board of the Worldwide Cannabinoid Affiliation for Drugs. He has a background in analytical chemistry and molecular pharmacology, and he acquired Ph.D. to characterize the structure and perform of cannabinoid receptors. He has written American Herbal Pharmacopeia's Cannabis Monograph and works with many skilled boards, trade affiliation committees and scientific organizations.
Dr. Marcu has helped create medical hashish training for docs and medical hashish staff, and has been invited to converse at many worldwide conferences and universities corresponding to Leiden University, Temple University Medical School, Princeton Hospital, and Yale College. Dr. Marcu can also be a authorized professional on hashish and synthetic cannabinoids.
Dr. Marcu is the recipient of the Billy Martin research award from the international cannabinoid group
from Blueberries Medical Corp.
Blueberries are a Latin American licensed producer of natural hashish whose main activities are ideally situated in Bogotá's Central Savannah, Colombia, and at present being established in Argentina. The corporate is run by a specialised staff with its own expertise in agriculture, genetics, extraction, drugs, pharmacology and advertising. Blueberries are licensed for the cultivation, manufacturing, home distribution and worldwide export of CBD and THC-based medical cannabis in Colombia. The mixture of blueberries with leading scientific experience, agricultural interests and distribution preparations has led the company to turn out to be a number one worldwide supplier of naturally grown, processed and standardized medical cannabis oil extracts and associated products.